Table 3.
Odds ratios and 95% confidence intervals for prostate cancer associated with specific features of metabolic syndrome among GECAP participants.
| Cases n (%) | Controls n (%) | All Men | Caucasian | African American | |
|---|---|---|---|---|---|
| Features of Metabolic Syndrome | Adjusted* OR (95% CI) | ||||
| Hypertension | 399 (62.7) | 146 (60.3) | 1.02 (0.73,1.43) | 1.30 (0.83,2.02) | 0.71 (0.42,1.23) |
| Diabetes | 123 (19.3) | 42 (17.4) | 1.12 (0.75,1.69) | 0.86 (0.47,1.59) | 1.34 (0.75,2.38) |
| Obesity‡ (BMI ≥30 kg/m2) | 208 (32.7) | 91 (37.3) | 0.75 (0.54,1.03) | 0.51 (0.33,0.80) | 1.15 (0.70,1.89) |
| Low HDL (<40 mg/dl) | 125 (22.1) | 39 (19.3) | 1.14 (0.74,1.74) | 1.43 (0.81,2.53) | 0.91 (0.46,1.78) |
| High Triglycerides (>150 mg/dl) | 228 (40.0) | 70 (34.3) | 1.28 (0.90,1.82) | 1.14 (0.71,1.82) | 1.41 (0.79,2.52) |
| 3 or more features† | 164 (25.8) | 52 (21.3) | 1.28 (0.89,1.83) | 1.02 (0.64,1.62) | 1.71 (0.97,3.01) |
*
Individual feature models adjusted for age, prostate specific antigen screening history, and 4 remaining features. Metabolic syndrome (3+ features) adjusted for age, PSA screening history.
†
Metabolic syndrome defined as possession of at least 3 features consistent with ATP III criteria (hypertension, diabetes, obesity, low HDL cholesterol and high triglycerides).